Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 781 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Maxygen to receive $30m payment from Bayer

In July 2008, Maxygen sold the recombinant factor VIIa product candidate to Bayer along with its other hematology assets for an upfront cash payment of $90m. Under the

Arno gains orphan-drug status for AR-42 in Europe

AR-42 is a broad-spectrum deacetylation inhibitor of both histone and non-histone proteins. The orally available inhibitor has demonstrated greater potency and activity in solid tumours and hematological malignancies